# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sabf6ba7ec4
CUTOFF DATE (today): 2022-12-10
Regulator: FDA (US)
Matter: FDA draft guidance: Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-12-01 | official-forward (B) | draft_guidance_availability_notice | "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific recommendations pertinent to gastric pH- dependent drug-drug interaction (DDI) assessment and describes the FDA's recommendations regarding when clinical DDI studies with acid- reducing agents (ARAs) are needed; design of the clinical studies; interpretation of study results; and communicating findings and options for managing pH-dependent DDIs in product labeling.
---
## SNAPSHOT S47ad8dfe73
CUTOFF DATE (today): 2022-06-09
Regulator: FDA (US)
Matter: FDA draft guidance: Drug Products Labeled as Homeopathic
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (2 item(s), chronological):
[E1] 2019-10-24 | official-forward (B) | draft_guidance_availability_notice | "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for FDA staff and industry entitled "Drug Products Labeled as Homeopathic." The revised draft guidance, like the original version, describes how FDA intends to prioritize enforcement and regul
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for FDA staff and industry entitled "Drug Products Labeled as Homeopathic." The revised draft guidance, like the original version, describes how FDA intends to prioritize enforcement and regulatory action with regard to drug products, including biological products, labeled as homeopathic and marketed in the United States without the required FDA approval that potentially pose higher risk to public health. In response to comments received, we have revised the draft guidance and are reissuing it in draft form to enable the public to review and comment before it is finalized.
[E2] 2020-03-13 | official-forward (B) | comment_period_extension_notice | "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry; Extension of Comment Period" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is extending the comment period for the notice entitled "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" that appeared in the Federal Register of October 25, 2019. The Agency is taking this act
   Excerpt: The Food and Drug Administration (FDA or Agency) is extending the comment period for the notice entitled "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" that appeared in the Federal Register of October 25, 2019. The Agency is taking this action to allow interested persons additional time to submit comments.
---
## SNAPSHOT Sb2bc14edad
CUTOFF DATE (today): 2025-12-10
Regulator: SEBI (IN)
Matter: SEBI consultation: clarifying the timeline for transferring unclaimed amounts to the investor protection fund for listed non-convertible securities
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9fc3c6acf6
CUTOFF DATE (today): 2026-05-01
Regulator: SEBI (IN)
Matter: SEBI consultation: uniform time lag for sharing and usage of price data for educational purposes
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9988fc2b2b
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: proposed amendments to the certification regime for associated persons in the securities markets
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S7506976024
CUTOFF DATE (today): 2022-01-23
Regulator: FDA (US)
Matter: FDA draft guidance: Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6c8aa92f30
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: harmonizing base price for pre-open call auction and price bands for stocks listed on multiple exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-06-11 | official-forward (B) | consultation_paper | "Consultation Paper on Harmonization of Base price for Call Auction in Pre-open Session and for Price Band - For scrips listed on multiple stock exchanges" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to harmonize the base price for the pre-open call-auction session, and price bands, for scrips listed on more than one recognized stock exchange. / Notes existing rule (Master Circular Para 2.3) prescribing individual scrip-wise price bands of up to 20% either way for scrips without derivatives products. / Notes existing rule (Master Circular Para 17.1.6) that price bands in the pre-open session equal those applicable in the normal market. / Frames the issue as inconsistency that can arise when a scrip is listed on multiple exchanges, each of which may independently apply these base-price/price-band rules.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to harmonize the base price for call auction in pre-open session and for setting up price bands for scrips listed on multiple stock exchanges. Background: As a measure against excessive price movements, SEBI vide circular No. SMDRPD/Policy/Cir-37/2001 dated June 28, 2001 has advised stock exchanges to implement individual scrip wise price bands of 20% either way, for all scrips in compulsory rolling settlement except for the scrips on which derivatives products are available or scrips included in indices on which derivatives products are available.
---
## SNAPSHOT S74818f8d55
CUTOFF DATE (today): 2026-06-10
Regulator: SEBI (IN)
Matter: SEBI consultation: revising the method for calculating variable net worth of stock brokers
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-04-24 | official-forward (B) | consultation_paper | "Consultation paper on Review of variable net worth for stock brokers" | www.sebi.gov.in
   Claims: Proposes a revised method for calculating the 'variable net worth' stock brokers must maintain, replacing the 2022 method based on average daily client cash balance. / States the 2022 method is no longer effective because the upstreaming framework now requires brokers to transfer client funds to clearing members/clearing corporations, leaving minimal client cash with brokers. / The proposed draft circular, developed by a Working Group of NSE, BSE and Broker Associations, sets out an alternative calculation method for public comment.
   Excerpt: As part of comprehensive risk management framework and to protect the interest of investors by aligning the net worth requirement with the operational risk being taken by the stock broker ('broker') with respect to its clients, the concept of variable net worth was introduced vide SEBI (Stock Brokers) (Amendment) Regulations, 2022... with the introduction of upstreaming framework mandating that clients' funds shall be up-streamed by broker to clearing members/clearing corporations, there is minimal amount of cash balance of clients which is retained by broker. Consequently, calculation of variable net worth of the brokers based on availability of funds with them may not be an effective way of calculating variable net worth.
---
## SNAPSHOT Sc195df9253
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: investor consent and conflicted-transaction thresholds for Alternative Investment Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb63c4dbcf3
CUTOFF DATE (today): 2026-03-05
Regulator: FDA (US)
Matter: FDA draft guidance: Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sc9aaa2d603
CUTOFF DATE (today): 2025-07-31
Regulator: FDA (US)
Matter: FDA draft guidance: Benefit-Risk Considerations for Product Quality Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sa222a97d6c
CUTOFF DATE (today): 2024-07-11
Regulator: FDA (US)
Matter: FDA draft guidance: Mpox: Development of Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-01-20 | official-forward (B) | draft_guidance_availability_notice | "Mpox: Development of Drugs and Biological Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
---
## SNAPSHOT S9b297364e6
CUTOFF DATE (today): 2021-09-05
Regulator: FDA (US)
Matter: FDA draft guidance: Biomarkers and Surrogate Endpoints in Clinical Studies To Support Effectiveness of New Animal Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-07-15 | official-forward (B) | draft_guidance_availability_notice | "Biomarkers and Surrogate Endpoints in Clinical Studies To Support Effectiveness of New Animal Drugs; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #267 entitled "Biomarkers and Surrogate Endpoints in Clinical Studies Support Effectiveness of New Animal Drugs." The draft guidance, if finalized, will describe FDA's current think
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #267 entitled "Biomarkers and Surrogate Endpoints in Clinical Studies Support Effectiveness of New Animal Drugs." The draft guidance, if finalized, will describe FDA's current thinking with respect to assisting sponsors in incorporating biomarkers and surrogate endpoints into proposed clinical investigation protocols and applications for new animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
---
## SNAPSHOT Scc2979067a
CUTOFF DATE (today): 2026-03-16
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business measures for Real Estate Investment Trusts and Infrastructure Investment Trusts
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-05 | official-forward (B) | consultation_paper | "Consultation Paper on Measures towards Ease of Doing Business for REITs and InvITs" | www.sebi.gov.in
   Claims: Proposes ease-of-doing-business amendments to SEBI (Infrastructure Investment Trusts) Regulations, 2014 and SEBI (Real Estate Investment Trusts) Regulations, 2014. / Proposes expanding the liquid mutual fund schemes REITs/InvITs may invest in for temporary fund deployment (relaxing the credit-risk-value/potential-risk-class criteria). / Proposes addressing practical difficulty where an InvIT SPV must continue holding an asset after conclusion of a concession agreement (due to pending claims/litigation/defect-liability periods). / Part of a Department of Debt and Hybrid Securities consultation based on Hybrid Securities Advisory Committee (HySAC) deliberations.
   Excerpt: CONSULTATION PAPER, DEPARTMENT OF DEBT AND HYBRID SECURITIES - POD II, CONSULTATION PAPER ON MEASURES TOWARDS EASE OF DOING BUSINESS FOR REITS AND InvITS, Feb 05, 2026.
---
## SNAPSHOT S7919d215da
CUTOFF DATE (today): 2024-10-10
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-10-06 | official-forward (B) | draft_guidance_availability_notice | "Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." The purpose of this draft guidance is to provide information and recommendations on the Generic 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." The purpose of this draft guidance is to provide information and recommendations on the Generic Drug User Fee Amendments (GDUFA) III program enhancements agreed upon by the Agency and industry in "GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027" (GDUFA III commitment letter), related to the early assessment of certain Type II drug master files (DMFs) 6 months prior to the submission of certain abbreviated new drug applications (ANDAs) or prior approval supplements (PASs). This draft guidance describes the process outlined in the GDUFA III commitment letter in greater detail and provides recommendations to DMF holders on how to provide the relevant information to FDA.
---
## SNAPSHOT Sb4b0b7c9bb
CUTOFF DATE (today): 2026-04-05
Regulator: SEBI (IN)
Matter: SEBI consultation: draft circular defining the AUM threshold for 'Significant Indices' under the Index Providers Regulations
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-01-19 | official-forward (B) | draft_circular_for_comment | "Consultation Paper on Circular under SEBI (Index Providers) Regulations, 2024" | www.sebi.gov.in
   Claims: Proposes a draft circular specifying the cumulative AUM threshold (and calculation method) above which an index is a 'Significant Index' under Index Providers Regulations, 2024, triggering regulatory applicability to its Index Provider. / Proposes the threshold at cumulative domestic mutual-fund AUM exceeding Rs 20,000 crore, computed as a monthly daily-average AUM. / States the draft circular's methodology and threshold were developed based on internal deliberations and discussions with the Association of Mutual Funds in India (AMFI).
   Excerpt: SEBI has notified the regulatory framework for Index Providers in the securities market through the SEBI (Index Provider) Regulations, 2024... with the objective of fostering transparency and accountability in governance and administration of Indices. The significant indices under the regulation were defined as 'Indices administered by an Index Provider, which are tracked or benchmarked by domestic mutual fund schemes with the cumulative assets under management exceeding the limits as may be specified from time to time.' Based on the internal deliberations and discussions with Association of Mutual Funds in India (AMFI), the draft circular proposing the mentioned limit... is placed at Annexure-1.
---
## SNAPSHOT S3a17e76d19
CUTOFF DATE (today): 2026-06-14
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing the pre-open call auction price-discovery mechanism for IPO listings and re-listed scrips
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-21 | official-forward (B) | consultation_paper | "Consultation Paper on Review of price discovery mechanism through Pre-open Call Auction Session for IPO and Re-listed scrips" | www.sebi.gov.in
   Claims: Seeks comments on reviewing the price-discovery mechanism of the Pre-open Call Auction Session used for IPO listings and re-listed scrips. / Describes the existing 60-minute session structure (45 min order entry/modification/cancellation, 10 min matching, 5 min buffer) with random closure between the 35th and 45th minute. / Notes there is currently no price band in this Call Auction Session and that market orders are not allowed. / Frames the review as addressing price-discovery/volatility concerns on the day of listing or re-listing.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to review the price discovery mechanism through Pre-open Call Auction Session (hereinafter referred as 'Call Auction Session') for IPO and re-listed scrips on the date of their listing or re-listing. A Call Auction Session for IPO and re-listed scrips was introduced by SEBI vide its circular No. CIR/MRD/DP/01/2012 dated January 20, 2012.
---
## SNAPSHOT Seeaf58b07c
CUTOFF DATE (today): 2022-01-15
Regulator: FDA (US)
Matter: FDA draft guidance: Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb79ad92c57
CUTOFF DATE (today): 2026-07-25
Regulator: SEBI (IN)
Matter: SEBI consultation: framework for an IT Resilience Index for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S458904925a
CUTOFF DATE (today): 2025-11-10
Regulator: FDA (US)
Matter: FDA draft guidance: Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.